Lentiviral Vectors in Immunotherapy

Dufait, Inès; Liechtenstein, Therese; Lanna, Alessio; Laranga, Roberta; Padella, Antonella; Bricogne, Christopher; Arce, Frederick; Kochan, Grazyna; Breckpot, Karine; Escors, David

doi:10.5772/50717

Cited by 2 publications

(2 citation statements)

References 122 publications

(166 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 2012, the results from clinical trials evaluating the PD-L1/PD-1 blockade were published, uncovering unprecedented efficacies in a wide range of tumors [ 1 , 2 ]. Immunotherapies had been extensively developed for several decades before this time [ 3 , 4 , 5 , 6 , 7 , 8 ], but never with the efficacies as reported for the PD-L1/PD-1 blockade. This change in paradigm had already started with the development of ipilimumab, a CTLA-4 blocking antibody [ 9 , 10 , 11 , 12 ].…”

Section: Introductionmentioning

confidence: 99%

Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy

Escors

Bocanegra

Chocarro

et al. 2022

IJMS

View full text Add to dashboard Cite

PD-L1/PD-1 blockade immunotherapy has changed the therapeutic approaches for the treatment of many cancers. Nevertheless, the mechanisms underlying its efficacy or treatment failure are still unclear. Proficient systemic immunity seems to be a prerequisite for efficacy, as recently shown in patients and in mouse models. It is widely accepted that expansion of anti-tumor CD8 T cell populations is principally responsible for anti-tumor responses. In contrast, the role of CD4 T cells has been less studied. Here we review and discuss the evidence supporting the contribution of CD4 T cells to anti-tumor immunity, especially recent advances linking CD4 T cell subsets to efficacious PD-L1/PD-1 blockade immunotherapy. We also discuss the role of CD4 T cell memory subsets present in peripheral blood before the start of immunotherapies, and their utility as predictors of response.

show abstract

Section: Introductionmentioning

confidence: 99%

Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy

Escors

Bocanegra

Chocarro

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…CARs are often delivered to T-cells with lentiviral vectors derived mainly from the HIV-1 genome. These vectors stably integrate their RNA genome into host cell genomes of dividing or non-proliferating immune cells in the form of a cDNA copy that is reverse transcribed into DNA in the target cell [ 331 , 332 ]. Lentiviruses carry a lower risk of insertional mutagenesis compared with other retroviruses that can only infect dividing cells, since they integrate into the host genome at sites away from gene promoters [ 333 , 334 ].…”

Section: Agents and Strategies For Cancer Immunotherapymentioning

confidence: 99%

Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy

Macpherson

Barry

Ricciardelli

et al. 2020

JCM

View full text Add to dashboard Cite

Recent advances in the understanding of immune function and the interactions with tumour cells have led to the development of various cancer immunotherapies and strategies for specific cancer types. However, despite some stunning successes with some malignancies such as melanomas and lung cancer, most patients receive little or no benefit from immunotherapy, which has been attributed to the tumour microenvironment and immune evasion. Although the US Food and Drug Administration have approved immunotherapies for some cancers, to date, only the anti-angiogenic antibody bevacizumab is approved for the treatment of epithelial ovarian cancer. Immunotherapeutic strategies for ovarian cancer are still under development and being tested in numerous clinical trials. A detailed understanding of the interactions between cancer and the immune system is vital for optimisation of immunotherapies either alone or when combined with chemotherapy and other therapies. This article, in two main parts, provides an overview of: (1) components of the normal immune system and current knowledge regarding tumour immunology, biology and their interactions; (2) strategies, and targets, together with challenges and potential innovative approaches for cancer immunotherapy, with attention given to epithelial ovarian cancer.

show abstract

Lentiviral Vectors in Immunotherapy

Cited by 2 publications

References 122 publications

Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy

Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy

Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy

Contact Info

Product

Resources

About